Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.72, $0.12 better than the analyst estimate of $0.60. Revenue for the quarter came in at $25.6 million versus the consensus estimate of $28.19 million.

“We ended 2015 and entered 2016 with strong momentum in all aspects of our business -- commercial, clinical, operational, and financial,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “First, product revenue increased 43% year-over-year for the fourth quarter, and our viscosupplementation franchise delivered robust performance and remained on track for market leadership in 2017. Second, we continued to advance our late-stage HA-based pipeline candidates, CINGAL and HYALOFAST, through the clinical development and regulatory channels. Third, as part of our strategic shift towards direct commercialization, we are consolidating our global manufacturing operations at our U.S. headquarters. Finally, we renewed our interest in strategic M&A opportunities that could augment our thriving organic business, and create value for shareholders over the short and long terms.”

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.